442 related articles for article (PubMed ID: 32967632)
1. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
[TBL] [Abstract][Full Text] [Related]
3. Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Ogata Y
Oncology; 2019; 96(6):290-298. PubMed ID: 30909286
[TBL] [Abstract][Full Text] [Related]
4. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma.
Kitano Y; Yamashita YI; Yamamura K; Arima K; Kaida T; Miyata T; Nakagawa S; Mima K; Imai K; Hashimoto D; Chikamoto A; Baba H
Anticancer Res; 2017 Jun; 37(6):3229-3237. PubMed ID: 28551669
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Cho H; Yoo C; Kim KP; Jeong JH; Kang J; Chang HM; Lee SS; Park DH; Song TJ; Lee SK; Kim MH; Lee HC; Lim YS; Kim KM; Shim JH; Hwang S; Song GW; Moon DB; Lee JH; Lee YJ; Ryoo BY
Invest New Drugs; 2018 Jun; 36(3):496-502. PubMed ID: 29192354
[TBL] [Abstract][Full Text] [Related]
7. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin.
Lee SY; Kim HS; Choi YJ; Park KH; Shin SW; Kim YH; Tae Kim S
Am J Ther; 2016; 23(6):e1449-e1455. PubMed ID: 25285672
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
10. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
[No Abstract] [Full Text] [Related]
11. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
12. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy.
Choi YH; Lee JW; Lee SH; Choi JH; Kang J; Lee BS; Paik WH; Ryu JK; Kim YT
Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1045-1051. PubMed ID: 30842131
[TBL] [Abstract][Full Text] [Related]
13. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.
Miyahara Y; Takashi S; Shimizu Y; Ohtsuka M
World J Surg Oncol; 2020 Apr; 18(1):78. PubMed ID: 32321522
[TBL] [Abstract][Full Text] [Related]
15. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma.
Maßmann M; Treckmann J; Markus P; Schumacher B; Albers D; Ting S; Mende B; Roehrle J; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Schmid KW; Baba H; Siveke JT; Paul A; Schildhaus HU; Schuler M; Wiesweg M; Kasper S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5085-5094. PubMed ID: 36334155
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.
Sellers CM; Uhlig J; Ludwig JM; Stein SM; Kim HS
Cancer Med; 2019 Oct; 8(13):5916-5929. PubMed ID: 31429524
[TBL] [Abstract][Full Text] [Related]
17. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Lee BM; Chung SY; Chang JS; Lee KJ; Seong J
Gut Liver; 2018 May; 12(3):342-352. PubMed ID: 29409306
[TBL] [Abstract][Full Text] [Related]
18. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
20. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]